The current stock price of PTHL is 0.9023 USD. In the past month the price increased by 80.28%. In the past year, price decreased by -76.5%.
ChartMill assigns a technical rating of 3 / 10 to PTHL. When comparing the yearly performance of all stocks, PTHL is a bad performer in the overall market: 82.97% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to PTHL. While PTHL seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months PTHL reported a non-GAAP Earnings per Share(EPS) of -0.16. The EPS decreased by -228.06% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -47.18% | ||
| ROE | -50.99% | ||
| Debt/Equity | 0.03 |
Pheton Holdings Ltd. operates as a holding company with interests in providing healthcare solutions. The company is headquartered in Beijing, Beijing and currently employs 10 full-time employees. The company went IPO on 2024-09-05. The Company’s main businesses include development and commercialization of brachytherapy treatment planning system (TPS) specifically used for radioactive particle implantation, a type of radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. TPS is generally a computer software used in different types of radiotherapy. The Company’s main product is FTTPS, a user-oriented TPS for treating a wide variety of malignant tumors. Beijing Feitian’s product portfolio also includes Medical Auxiliary Supplies such as seed implant needles, computer workstations, patient positioning device and others.
PHETON HOLDINGS LTD-A
Room 306, NET Building, Hongjunying South Road, Chaoyang District
Beijing BEIJING CN
Employees: 10
Phone: 861084817665
Pheton Holdings Ltd. operates as a holding company with interests in providing healthcare solutions. The company is headquartered in Beijing, Beijing and currently employs 10 full-time employees. The company went IPO on 2024-09-05. The Company’s main businesses include development and commercialization of brachytherapy treatment planning system (TPS) specifically used for radioactive particle implantation, a type of radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. TPS is generally a computer software used in different types of radiotherapy. The Company’s main product is FTTPS, a user-oriented TPS for treating a wide variety of malignant tumors. Beijing Feitian’s product portfolio also includes Medical Auxiliary Supplies such as seed implant needles, computer workstations, patient positioning device and others.
The current stock price of PTHL is 0.9023 USD. The price increased by 105.16% in the last trading session.
PTHL does not pay a dividend.
PTHL has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.